A strong development pipeline for regenerative medicine (RM) therapies designed to treat a range of unmet medical needs suggests the potential for rapid growth in global sales of products that could offer significant benefits to public health, according to an analysis by the Tufts Center for the Study of Drug Development (CSDD).